Therapeutic Apheresis · Review 04
INUSpheresis: what the filter removes, and what outcomes remain unproven
Proteomic and Long COVID studies show measurable removal of circulating factors. That is not yet equivalent to demonstrated patient benefit for broad preventive or post-viral use.
- PROCEDURE STATUS
- Filtration-based therapeutic apheresis system
- INDICATION EVIDENCE
- Mechanism documented; broad outcome claims unproven
- REVIEW STATUS
- Clinical review required
- NEXT REVIEW
- January 2027
In short
INUSpheresis can measurably reduce selected lipids, inflammatory proteins, fibrinogen, autoantibodies and other circulating molecules. The strongest published evidence describes what different filters remove. Controlled evidence has not yet shown that this broad removal produces clinical benefit for longevity, general prevention or Long COVID.
The clinical question
What does INUSpheresis measurably remove, and which patient benefits have been demonstrated in controlled studies?
What the published studies actually tested
INUSpheresis is a filtration-based therapeutic apheresis approach. A 2022 proteomic study used differently sized filters in patients receiving lipoprotein apheresis and found that filters removed different quantities of apolipoproteins, C-reactive protein, fibrinogen, plasminogen and other proteins associated with cardiometabolic risk.[1]
A 2023 Long COVID cohort documented reductions in autoantibodies, inflammatory markers, oxidative measures, lipids and fibrinogen after treatment. These findings demonstrate biological action and provide hypotheses for future trials.[2]
Why filter performance and clinical benefit are different questions
A filter study can establish that a molecule was removed. A clinical-outcome study must establish that patients function or feel better because of the intervention, compared with an appropriate control, for long enough to matter. The current INUSpheresis literature does not close that causal gap for broad preventive, longevity or Long COVID claims.[1][2][3]
Selectivity has two sides
Removing several potentially harmful factors may be useful in the right indication. Broad filtration can also remove proteins with useful functions, so more removal is not automatically a better clinical result.
What cannot be safely extrapolated
Evidence from patients with severe inherited lipid disorders cannot be treated as evidence for healthy longevity clients. Evidence that INUSpheresis changes Long COVID biomarkers cannot be treated as proof of symptom efficacy. Evidence from conventional plasma exchange cannot automatically prove a device-specific effect for cascade filtration.[1][2][3]
- Name the exact filter system and indication.
- Separate immediate removal from durable change.
- Report patient outcomes independently from laboratory outcomes.
- Disclose when evidence comes from a different patient population.
What this means for you
INUSpheresis is explained to you through a precise indication and a measurable clinical rationale, not a general list of substances the filter might remove. Because any benefit claim requires outcome evidence for that same population and use, whether you are eligible remains a physician decision.[1][3]
Source register
Every material source used in this review, with the study design and the limitation that matters when interpreting it.
- [1]Yin X, et al. Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis.
Hormone and Metabolic Research · 2022 · Human proteomic filter-comparison study
PMID 35413745 · DOI 10.1055/a-1776-7943
- WHAT IT ADDS
- Shows that different INUSpheresis filters remove different quantities of cardiometabolic proteins.
- LIMITATION
- Designed to characterize removal and biomarkers, not to prove broad patient-outcome benefits.
- [2]Achleitner M, et al. Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis.
Molecular Psychiatry · 2023 · Uncontrolled INUSpheresis biomarker cohort
PMID 37131073 · DOI 10.1038/s41380-023-02084-1
- WHAT IT ADDS
- Documents broad biomarker reductions after two treatments in 27 Long COVID patients.
- LIMITATION
- Selected patients reporting improvement, no sham group and no demonstration of causality.
- [3]Vidal-Alaball J, et al. Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial.
Nature Communications · 2025 · Randomized sham-controlled trial of plasma exchange
PMID 39994269 · DOI 10.1038/s41467-025-57198-7
- WHAT IT ADDS
- Found no efficacy difference for plasma exchange versus sham in Long COVID.
- LIMITATION
- Not an INUSpheresis device trial, so it raises the evidence threshold without directly testing the device.
Research changes the question.
A physician owns the answer.
This review is educational and remains marked for clinical review. It does not determine whether any therapy is appropriate for an individual patient.